Company intelligence / Profile preview

Purpose Pharma

Ownership: Private
Development stage: NDA

Overview

Purpose Pharma focuses on developing and commercializing innovative treatments for rare diseases and specialty care. Its lead product, Attrogy® (diflunisal), received a positive CHMP opinion from the European Medicines Agency in April 2025 for hereditary transthyretin-mediated amyloidosis. The company also supplies unlicensed medicines to address drug shortages in Sweden. Investors include Industrifonden and Eir Ventures, with an experienced leadership team from the Nordic biotech sector. The pipeline breadth appears limited but focused on high unmet needs.

Therapeutic areas: Rare Diseases
Modalities: Small molecules (diflunisal)
Industry: Biotech

Drug pipeline

1 asset

diflunisal

NDA

Indications: Transthyretin amyloid polyneuropathy (ATTR-PN)

Beyond the preview

Go deeper on Purpose Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Purpose Pharma.

Explore the full profile